Loading data for NERV — first visit, this takes a few seconds.

Alerta

Minerva Neurosciences Inc... (NERV)

NasdaqCM: NERV · Precio en tiempo real · USD

3.92

-0.40 (-9.26%)

Al cierre: Aug 12, 2026, 8:00 PM

3.95

+0.77%

Fuera de horario: 7:46 PM

-9.26% (1D)

No hay datos disponibles

Precio de compra	3.19
Capitalización de mercado	187.17M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-394.35M
Beta	-0.11
EPS (TTM)	-32.78
Ratio PER (TTM)	n/a
Adelante PE	-9.33
P/B (TTM)	-0.68
P/S (TTM)	n/a
Earnings Date	Aug 5, 2025

Precio de venta	5.41
Volumen	138,129
Volumen medio (20D)	225,700
Abierto	4.31
Anterior Cerrar	4.32
Rango del día	3.90 - 4.56
Rango de 52 semanas	1.76 - 12.46
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts....

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jul 1, 2014

Empleados 7

Bolsa de Valores NasdaqCM

Símbolo bursátil NERV

Sitio web https://www.minervaneurosciences.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Minerva Neurosciences fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -293.42M, una disminución de -20,492.68%.

Estados financieros

Sorpresa de resultados

Minerva Neurosciences ha publicado sus resultados trimestrales en Aug 7, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.17 falla las estimaciones por -0.16, con 60.47% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Minerva Neurosciences Inc. publique sus resultados el Aug 5, 2025, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

3 meses hace · Zacks

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 meses hace · Zacks

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre...

5 meses hace · MarketBeat

Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms

Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of ...

5 meses hace · Associated Press Finance

Minerva Neurosciences: Q4 Earnings Snapshot

BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $283.7 million in its fourth quarter.

6 meses hace · Simply Wall St.

Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most

Key Insights Minerva Neurosciences' significant individual investors ownership suggests that the key decisions are...

Página 1 de 2

Minerva Neurosciences Inc... (NERV)